As a follow-up to our original post concerning delisting of certain Orang Book patents, on 2/24/23 the Federal Circuit affirmed an earlier district court decision that a REMS patent issued to Jazz Pharma failed “to claim a drug or method of use" and U.S. Patent 8,731,963 should be delisted.

A copy of the opinion can be found here: https://cafc.uscourts.gov/opinions-orders/23-1186.OPINION.2-24-2023_2085825.pdf

#patents
#pharmaceutical
#Oraange Book
#REMS